Top Diabetic Neuropathy Companies

Skyquest Technology's expert advisors have carried out comprehensive research and identified these companies as industry leaders in the Diabetic Neuropathy Market. This Analysis is based on comprehensive primary and secondary research on the corporate strategies, financial and operational performance, product portfolio, market share and brand analysis of all the leading Diabetic Neuropathy industry players.

Diabetic Neuropathy Market Competitive Landscape

Due to the rise in R&D projects, Johnson & Johnson and GlaxoSmithKline plc are the major players outperforming the diabetic neuropathy market. Major market companies are being influenced by this to diversify their product offerings globally. As a result, the important companies' varied product portfolios tend to increase the company's value. For instance, The most significant player in the market is thought to be Pfizer Inc. due to its emphasis on creating goods like Motrin and Lyrica that are expected to fuel growth.

Diabetic Neuropathy Market Top Players Company Profiles

  • Johnson & Johnson 
  • Pfizer Inc
  • Eli Lilly and Company
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline plc
  • Astellas Pharma Inc.
  • Novartis AG
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • AbbVie Inc.
  • Glenmark Pharmaceuticals Limited
  • Lupin Pharmaceuticals, Inc.
  • Intas Pharmaceuticals Ltd.
  • Alkem Laboratories Ltd.
  • Cipla Limited
  • Mylan N.V.
  • Zydus Cadila Healthcare Limited
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.

Diabetic Neuropathy Market Recent Development

  • In January 2022, FDA approved Spinal cord stimulation therapy, according to Medtronic, for the treatment of persistent pain brought on by diabetic peripheral neuropathy.
  • In December 2021, in order to develop "Ask your Doctor," the pharma business P&G Health, with its headquarters in India, collaborated with the English-language local newspaper Hindustan Times. The purpose of this online event is to inform the public about diabetic neuropathy and how to treat it.
REPORT OVERVIEW BUY NOW

REQUEST FOR SAMPLE

Want to customize this report? REQUEST FREE CUSTOMIZATION

FAQs

Diabetic Neuropathy Market size was valued at USD 4144.09 Million in 2024 and is poised to grow from USD 4430.03 Million in 2025 to USD 7554.89 Million by 2033, growing at a CAGR of 6.9% during the forecast period (2026–2033).

Due to the rise in R&D projects, Johnson & Johnson and GlaxoSmithKline plc are the major players outperforming the diabetic neuropathy market. Major market companies are being influenced by this to diversify their product offerings globally. As a result, the important companies' varied product portfolios tend to increase the company's value. For instance, The most significant player in the market is thought to be Pfizer Inc. due to its emphasis on creating goods like Motrin and Lyrica that are expected to fuel growth. 'Abbott Laboratories ', 'Eli Lilly and Company ', 'Pfizer Inc. ', 'F. Hoffmann-La Roche Ltd. ', 'GlaxoSmithKline plc ', 'Lupin Pharmaceuticals, Inc. ', 'Astellas Pharma US, Inc. ', 'Bayer AG ', 'Teva Pharmaceutical Industries Ltd. ', 'NeuroMetrix Inc. ', 'Helixmith Co., Ltd. ', 'Johnson & Johnson Services, Inc. ', 'Daiichi Sankyo Company, Limited ', 'Ionis Pharmaceuticals, Inc. ', 'Akcea Therapeutics, Inc. ', 'Alfasigma USA, Inc. ', 'ExeGi Pharma LLC '

Because of the rising prevalence of diabetes, global demand for diabetic neuropathy would grow at a slower rate during the projection period. Furthermore, obesity, coronary heart disease, diabetic neuropathy, and other sugar-related issues are thought to be some of the factors driving the market's expansion. The market's expansion is also influenced by rising urbanization, which promotes sedentary lifestyles such as carbohydrate consumption and low physical activity.

During the forecast year, high-tech goods will be developed for better diabetic neuropathy therapy. Companies are concentrating on creating transdermal patches, mouthwash, talc, as well as other products.  Manufacturers have introduced cutting-edge medication delivery systems, like syringe-free injection equipment, to combat problems related to surgical pharmaceuticals. As a result, NFIT has attracted significant interest in the treatment of the disease, which is helping the market expand. As a result, the market is expanding due to the rising demand for new drug delivery methods such as oral, transdermal, parenteral, and inhalation.

In 2021, the greatest market for diabetic neuropathy is in North America. In order to counteract the degradation of generic pharmaceuticals, pharma companies continue to give fresh medications in the area. Due to a big incidence of chronic diseases such as diabetes, and an increasing senior generation, diabetic neuropathy treatment has become extremely popular, particularly in the United States.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Diabetic Neuropathy Treatment Market
Buy Now GET FREE SAMPLE
Diabetic Retinopathy Market
Buy Now GET FREE SAMPLE
Diabetic Nephropathy Market
Buy Now GET FREE SAMPLE
Diabetic Food Market
Buy Now GET FREE SAMPLE
Neuropathic Pain Market
Buy Now GET FREE SAMPLE
Diabetic Foot Ulcer Treatment Market
Buy Now GET FREE SAMPLE
Diabetic Socks Market
Buy Now GET FREE SAMPLE
Peripheral Nerve Injuries Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Diabetic Neuropathy Market
Diabetic Neuropathy Market

Report ID: SQMIG35I2245

sales@skyquestt.com
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE